Announcements Trials
Browse Landscape

Phase

Phase 2/3 2

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2

Conditions

Lung Neoplasms 7Ovarian Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Fallopian Tube Neoplasms 4Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Pancreatic Neoplasms 3Endometrial Neoplasms 3Carcinoma, Renal Cell 3Urinary Bladder Neoplasms 2Oropharyngeal Neoplasms 2Nasopharyngeal Carcinoma 2Mycosis Fungoides 2Multiple Myeloma 2Mouth Neoplasms 2Melanoma 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Anaplastic 2Lymphoid Interstitial Pneumonia 2Laryngeal Neoplasms 2Hypopharyngeal Neoplasms 2Colonic Neoplasms 2Carcinoma 2Brenner Tumor 2Breast Neoplasms 2Adenocarcinoma of Lung 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Tongue Neoplasms 1

Interventions

Specimen Handling 5Magnetic Resonance Spectroscopy 5Cetuximab 3(225)Ac-DOTA-c(RGDyK) 3pembrolizumab 2Platinum 2Immunoglobulin G 2Disulfides 2Cisplatin 2Biopsy 21,2-diaminocyclohexaneplatinum II citrate 2ipatasertib 1durvalumab 1cabozantinib 1atezolizumab 1Surveys and Questionnaires 1Radiotherapy, Intensity-Modulated 1Radiotherapy 1Radiosurgery 1Radiation 1Nivolumab 1Docetaxel 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Hypopharyngeal Neoplasms × Immunoglobulin G × 30 days × Clear all
NCT05063552 2026-06-03

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
430 enrolled
Head & Neck

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT03258554 2026-06-02

Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin

National Cancer Institute (NCI)

Phase 2/3 Completed
196 enrolled 31 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡